Ashish Saxena, MD, PhD, discusses the importance of initial therapy selection in ALK-positive non–small cell lung cancer.
Ashish Saxena, MD, PhD
Advertisement
Articles by Ashish Saxena, MD, PhD
Advertisement
Latest Updated Articles
Dr. Saxena on the Importance of Initial Treatment Selection in ALK+ NSCLCPublished: January 24th 2020 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
FDA Decisions to Look For in 1H 2026
2
Ultragenyx Finishes Rolling Submission of BLA for Glycogen Storage Disease Gene Therapy DTX401
3
FDA Activity Recap: December 2025 Features Multiple Approvals, RMAT Designation, and More
4
Integrating AI Tools Into Clinical Practice for Genetic Counselors
5